Urinary Tract Cancer Market Forecast 2024-2033: Projected CAGR, Key Drivers, And Trends

Overview and Scope

Urinary tract cancer refers to malignancies that develop in the kidneys, bladder, ureters, or urethra, often causing symptoms like blood in the urine and pain. The preventive steps such as stopping smoking, avoiding hazardous substances and promptly treating urine infections may help minimize the risk of getting urinary tract cancer.

Sizing and Forecast

The urinary tract cancer market size has grown exponentially in recent years. It will grow from $2.65 billion in 2023 to $3.21 billion in 2024 at a compound annual growth rate (CAGR) of 21.1%. The growth in the historic period can be attributed to advancements in diagnostics, pharmaceutical developments, awareness and early detection, precision medicine.

The urinary tract cancer market size is expected to see rapid growth in the next few years. It will grow to $6.49 billion in 2028 at a compound annual growth rate (CAGR) of 19.3%. The growth in the forecast period can be attributed to immunotherapy advancements, telemedicine and remote monitoring, biomarker research, adjuvant therapies. Major trends in the forecast period include global collaboration, advances in palliative care, comprehensive survivorship programs, patient-centric care.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report

Segmentation & Regional Insights

The urinary tract cancer market covered in this report is segmented –

1) By Cancer Type: Bladder Cancer; Urethral Cancer; Ureteric And Renal Pelvic Cancer

2) By Treatment: Chemotherapy; Intravesical Therapy; Radiation Therapy; Surgery

3) By Diagnostic Techniques: Cystoscopy; Transurethral Resection Of The Tumor; Imaging Tests; Urine Analyses; Other Diagnostic Techniques

4) By Distribution Channel: Retail Pharmacy; Online Pharmacy

North America was the largest region in the urinary tract cancer market in 2023. The regions covered in urinary tract cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13059&type=smp

Major Driver Impacting Market Growth

The growing prevalence of bladder cancer is expected to propel the growth of the urinary tract cancer market. Bladder cancer refers to the development of cancerous cells within the tissues of the urinary bladder, which is a hollow organ in the pelvis responsible for storing urine produced by the kidneys until it is excreted from the body. This higher prevalence leads to greater demand for diagnostic tools, screening methods and treatment options for urinary tract cancer patients. For instance, in January 2023, according to the report published by the American Cancer Society Inc., a US-based voluntary organization for cancer awareness, the estimated cases of urinary system cancer increased to 168,560 in 2023, an increase of 2.66% from 164,190 in 2022 in the United States. Moreover, bladder cancer cases increased to 83,730 in 2021, an increase of 2.8% from 81,400 in 2020. Therefore, the growing prevalence of bladder cancer will drive the growth of the urinary tract cancer market.

Key Industry Players

Major players in the urinary tract cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck KGaA, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Eisai Co. Ltd., Boehringer Ingelheim GmbH, Incyte Corporation, Shionogi & Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Endo International PLC, Seagen Inc., Exelixis Inc., Ferring Pharmaceuticals, Bavarian Nordic, EUSA Pharma, UroGen Pharma Inc., Mersana Therapeutics, Protara Therapeutics Inc., Spectrum Pharmaceuticals, IDL Biotech AB, AroCell AB, ImmunityBio Inc.

The urinary tract cancer market report table of contents includes: